Mineralys Therapeutics announced on May 20, 2025, that data from its pivotal Phase 3 Launch-HTN trial was accepted for a late-breaking clinical trials session. The presentation will take place at the 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025), scheduled for May 23-26, 2025, in Milan.
This acceptance underscores the importance of lorundrostat's efficacy and safety data in a real-world setting for uncontrolled or resistant hypertension. A late-breaking slot at such a prominent international conference is reserved for significant and timely clinical research.
The presentation will offer detailed insights into lorundrostat's performance to a global audience of medical professionals and researchers. This exposure further validates the trial results and the drug's potential impact on hypertension care.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.